King Faisal Specialist Hospital in Saudi Arabia internally produced CAR T-cells for cancer treatment at 80% lower cost.

King Faisal Specialist Hospital & Research Centre in Saudi Arabia has successfully produced Chimeric Antigen Receptor (CAR) T-cells internally for cancer treatment, reducing treatment costs by 80% to approximately 250,000 SAR per treatment. The breakthrough overcomes cost and shipping challenges, providing faster access to treatment and supporting national efforts to localize biotechnological industries. The hospital's internal T-cell manufacturing centre uses advanced bioreactors and cell processing units and is part of an ongoing strategy to develop advanced therapies and increase clinical research opportunities to enhance healthcare quality.